Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review
Open Access
- 10 May 2018
- journal article
- review article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 103 (6), 931-938
- https://doi.org/10.3324/haematol.2017.186684
Abstract
Chronic lymphocytic leukemia is an extremely heterogeneous disease and prognostic factors such as chromosomal abnormalities are important predictors of time to first treatment and survival. Trisomy 12 is the second most frequent aberration detected by fluorescence in situ hybridization at the time of diagnosis (10% to 25%), and it confers an intermediate prognostic risk, with a median time to first treatment of 33 months and a median overall survival of 114 months. Here, we review the unique morphologic, immunophenotypic, and genetic characteristics of patients with chronic lymphocytic leukemia and trisomy 12. These patients carry a significantly higher expression of CD19, CD22, CD20, CD79b, CD24, CD27, CD38, CD49d, sIgM, sIgk, and sIgλ and lower expression of CD43 compared with patients with normal karyotype. Circulating cells show increased expression of the integrins CD11b, CD18, CD29, and ITGB7 and of the adhesion molecule CD323. Patients with chronic lymphocytic leukemia and trisomy 12 frequently have unmutated IGHV, ZAP-70 positivity, and closely homologous stereotyped B-cell receptors. They rarely show TP53 mutations but frequently have NOTCH1 mutations, which can be identified in up to 40% of those with a rapidly progressive clinical course.This publication has 99 references indexed in Scilit:
- A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemiaHematological Oncology, 2015
- The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trialBlood, 2013
- Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemiaBlood, 2012
- Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2011
- Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemiaNature, 2011
- Antigens in chronic lymphocytic leukemia—Implications for cell origin and leukemogenesisSeminars in Cancer Biology, 2010
- From pathogenesis to treatment of chronic lymphocytic leukaemiaNature Reviews Cancer, 2009
- Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance.2002
- Analysis of clonal B‐cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B‐chronic lymphocytic leukaemiaBritish Journal of Haematology, 2001
- Does IL-2 receptor expression and secretion in chronic B-cell leukemia have a role in down-regulation of the immune system?1994